Target type: cellularcomponent
A protein complex that possesses protein farnesyltransferase activity. [GOC:mah]
The farnesyltransferase complex is a multi-protein assembly responsible for the post-translational modification of proteins by attaching a farnesyl group, a 15-carbon isoprenoid, to cysteine residues near the C-terminus. This complex is localized to the cytoplasmic side of the endoplasmic reticulum membrane, and it is typically composed of two subunits: **Farnesyltransferase alpha subunit (α-FTase)** and **Farnesyltransferase beta subunit (β-FTase)**.
* **α-FTase:** This subunit is a 46 kDa protein that binds the farnesyl diphosphate (FPP) substrate. It also contains a catalytic site that interacts with the substrate protein.
* **β-FTase:** This subunit is a 48 kDa protein that binds the substrate protein. It also contains a cysteine residue that acts as the nucleophile in the transfer reaction.
The two subunits interact via a complex interface that facilitates the binding of both the protein substrate and the FPP substrate. This interaction is crucial for the proper functioning of the complex.
**Detailed description of the cellular component:**
1. **Localization:** The farnesyltransferase complex is primarily localized to the **cytoplasmic side of the endoplasmic reticulum (ER) membrane**. This localization is essential for the complex to access its protein substrates, which are often synthesized and processed in the ER.
2. **Membrane Association:** While the farnesyltransferase complex is associated with the ER membrane, it is not embedded within the membrane. Rather, it interacts with the membrane through **hydrophobic interactions** between specific amino acid residues within the complex and the lipid bilayer.
3. **Structure:** The complex has a **globular structure** with a well-defined active site that accommodates both the protein substrate and the FPP substrate.
4. **Dynamic Assembly:** The assembly of the α-FTase and β-FTase subunits into the active farnesyltransferase complex is a **dynamic process**. This process can be influenced by factors such as the concentration of substrate proteins and the availability of FPP.
In addition to these core components, other proteins may associate with the farnesyltransferase complex, including:
* **Rab escort protein (REP):** This protein assists in the delivery of Rab proteins to the farnesyltransferase complex.
* **Chaperone proteins:** These proteins can help to prevent misfolding and aggregation of the complex subunits.
**Importance of the Farnesyltransferase Complex:**
The farnesyltransferase complex plays a critical role in various cellular processes, including:
* **Signal transduction:** Farnesylation is essential for the proper function of a wide range of signaling proteins, including Ras GTPases.
* **Cellular trafficking:** Farnesylation of Rab proteins is crucial for their proper targeting and function in vesicle transport.
* **Nuclear localization:** Farnesylation can contribute to the localization of certain proteins to the nucleus.
**Regulation of Farnesyltransferase Activity:**
The activity of the farnesyltransferase complex is tightly regulated, and this regulation is essential for maintaining cellular homeostasis. Factors that influence the activity of the complex include:
* **Substrate availability:** The concentration of protein substrates and FPP can influence the activity of the complex.
* **Post-translational modifications:** The farnesyltransferase complex itself can be subject to post-translational modifications, such as phosphorylation, which can affect its activity.
* **Inhibitors:** Several small-molecule inhibitors have been developed that specifically target the farnesyltransferase complex, and these inhibitors have shown promise as potential therapeutic agents for various diseases.
In conclusion, the farnesyltransferase complex is a complex and dynamic assembly that plays a critical role in various cellular processes. Its localization to the ER membrane, its specific protein-protein interactions, and its tight regulation all contribute to its crucial function in cell signaling, trafficking, and other essential processes.'
"
Protein | Definition | Taxonomy |
---|---|---|
Protein farnesyltransferase subunit beta | A protein that is a translation product of the FNTB gene in cow. [PRO:DNx, UniProtKB:P49355] | Bos taurus (cattle) |
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | A protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha that is encoded in the genome of cow. [OMA:P29702, PRO:DNx] | Bos taurus (cattle) |
Protein farnesyltransferase subunit beta | A protein farnesyltransferase subunit beta that is encoded in the genome of human. [PRO:DNx, UniProtKB:P49356] | Homo sapiens (human) |
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | A protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha that is encoded in the genome of human. [PRO:DNx, UniProtKB:P49354] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
1,10-phenanthroline | 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases | phenanthroline | EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor |
2,2'-dipyridyl | 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'. 2,2'-Dipyridyl: A reagent used for the determination of iron. | bipyridine | chelator; ferroptosis inhibitor |
ethylenediamine | ethylenediamine : An alkane-alpha,omega-diamine in which the alkane is ethane. ethylenediamine: RN given refers to parent cpd; edamine is the recommended contraction for the ethylenediamine radical | alkane-alpha,omega-diamine | GABA agonist |
cortisone acetate | Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders. | corticosteroid hormone | |
gliotoxin | gliotoxin : A pyrazinoindole with a disulfide bridge spanning a dioxo-substituted pyrazine ring; mycotoxin produced by several species of fungi. Gliotoxin: A fungal toxin produced by various species of Trichoderma, Gladiocladium fimbriatum, Aspergillus fumigatus, and Penicillium. It is used as an immunosuppressive agent. | dipeptide; organic disulfide; organic heterotetracyclic compound; pyrazinoindole | antifungal agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; immunosuppressive agent; mycotoxin; proteasome inhibitor |
sch 37370 | N-acetyldesloratadine: dual antagonist of platelet-activating factor and histamine | ||
desloratadine | desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. desloratadine: major metabolite of loratadine | benzocycloheptapyridine | anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist |
b 581 | B 581 : A dipeptide obtained from the tetrapeptide Cys-Val-Phe-Met by reduction of the amide carbonyl groups of the Cys and Val residues. B 581: blocks farnesylated but not geranylgeranylated or myristylated, oncogenic Ras signaling & transformation | dipeptide | EC 2.5.1.58 (protein farnesyltransferase) inhibitor; peptidomimetic |
r115777 | |||
lonafarnib | lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor. lonafarnib: inhibitor of farnesyl protein transferase | 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide | antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor |
tipifarnib | imidazoles; monochlorobenzenes; primary amino compound; quinolone | antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor | |
l 778,123 | L-778,123 (free base) : A member of the class of imidazoles that is 1H-imidazole substituted by (4-cyanophenyl)methyl and [4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl groups at positions 1 and 5, respectively. It is a dual inhibitor of FPTase and GGPTase-I. | imidazoles; monochlorobenzenes; nitrile; piperazinone; tertiary amino compound | antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor |
halenaquinone | halenaquinone: RN given refers to (S)-isomer; structure in first source | ||
fti 276 | FTI 276: a ras CAAX (C - Cys; A - aliphatic amino acid; X - Ser or Met) peptidomimetic; inhibits farnesyltransferase; FTI-277 is the methyl ester derivative of FTI-276 | methionine derivative | |
lb42908 | LB42908 : A member of the class of pyrrolecarboxamides that is 1H-pyrrole substituted by [1-(3a,7a-dihydro-1,3-benzodioxol-5-ylmethyl)-1H-imidazol-5-yl]methyl, (4-methylpiperazin-1-yl)carbonyl, and naphthalen-1-yl groups at positions 1, 3 and 4, respectively. It is a potent inhibitor of Ras farnesyltransferase (IC50= 0.9nM against H-Ras and 2.4nM against K-Ras) with potential anticancer activity. LB42908: structure in first source | ||
farnesyl pyrophosphate | 2-trans,6-trans-farnesyl diphosphate : The trans,trans-stereoisomer of farnesyl diphosphate. farnesyl pyrophosphate: a sesquiterpene that dimerizes to SQUALENE; RN given refers to cpd without isomeric designation | farnesyl diphosphate | Escherichia coli metabolite; mouse metabolite |
a 228839 | A 228839: an immunosuppressive agent; structure in first source | ||
bms 214662 | 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors. | benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes | antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor |
fti 277 | |||
ggti 286 | GGTI 286: the methyl ester of GGTI-287; inhibits geranylgeranyltransferase | ||
chaetomellic acid a | chaetomellic acid A: structure given in first source; an inhibitor of farnesyl-protein transferase | ||
kurasoin a | kurasoin A: protein farnesyltransferase inhibitor; isolated from Paecilomyces; structure in first source | ||
kurasoin b | kurasoin B: protein farnesyltransferase inhibitor; isolated from Paecilomyces; structure in first source | ||
manumycin | manumycin A : A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. manumycin: an NSAID; RN given for (1S-(1alpha,3(2E,4E,6S*),5alpha,5(1E,3E,5E),6alpha))-isomer; a farnesyl protein transferase inhibitor; from Streptomyces parvulus; MF C31-H38-N2-O7; structure given in first source | enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol | antiatherosclerotic agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; marine metabolite |
clavaric acid | clavaric acid: inhibits farnesyl-protein transferase; isolated from Clavariadelphus truncatus; structure in first source | ||
ggti 298 | GGTI 298: inhibits geranylgeranyltransferase-I; structure in first source | leucine derivative | |
sch 44342 | SCH 44342: inhibits farnesyl protein transferase; structure in first source | ||
lonafarnib | 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide : A benzocycloheptapyridine that is benzo[5,6]cyclohepta[1,2-b]pyridine which is substituted at positions 3 and 10 by bromines, at position 8 by chlorine, and at position 11 by an N-acetylpiperidin-4-yl group in which one of the hydrogens of the acetyl moiety has been replaced by a 1-carbamoylpiperidin-4-yl group. | benzocycloheptapyridine; heteroarylpiperidine; N-acylpiperidine; organobromine compound; organochlorine compound; ureas | |
lb42708 | LB42708: farnesyltransferase inhibitor; structure in first source | ||
actinoplanic acid a | actinoplanic acid A: isolated from Actinoplanes; inhibits farnesyl-protein transferase; structure in first source | ||
moverastin a | moverastin A: inhibits cancer cell migration; isolated from Aspergillus; structure in first source |